X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/acepodia-announces-fda-clearance-of-investigational-new-drug-application-for-ace2016-a-first-in-class-allogeneic-anti-egfr-cell-therapy-302052466.html
https://www.fiercebiotech.com/biotech/nobel-laureate-bertozzi-joins-acepodia-biotech-aims-transform-cancer-cell-therapy
https://www.fiercebiotech.com/biotech/acepodia-picks-strong-hand-advance-cell-therapies-100m-series-d
https://www.prnewswire.com/news-releases/acepodia-to-present-preclinical-data-of-gamma-delta-t-cell-therapy-candidate-ace2016-an-off-the-shelf-egfr-targeting-2-t-cell-therapy-against-egfr-expressing-solid-tumors-301781783.html
https://www.fiercebiotech.com/biotech/acepodia-secures-109m-series-c-to-bankroll-cell-therapy-for-her2-cancers
https://www.globenewswire.com/news-release/2021/12/02/2345016/0/en/Acepodia-Raises-109-Million-Series-C-Financing-to-Advance-Development-of-First-in-Class-Antibody-Cell-Effector-Therapies.html
https://www.globenewswire.com/news-release/2021/09/16/2298101/0/en/Acepodia-Presents-Positive-Interim-Phase-1-Feasibility-Data-for-Antibody-Cell-Effector-Therapy-ACE1702-in-Advanced-HER2-Positive-Tumors.html
https://www.globenewswire.com/news-release/2021/09/13/2295739/0/en/Acepodia-to-Present-Data-from-Preclinical-and-Phase-1-Studies-of-ACE1702-at-the-European-Society-for-Medical-Oncology-ESMO-2021-Virtual-Congress.html
https://www.globenewswire.com/news-release/2021/06/07/2242661/0/en/Acepodia-Publishes-Preclinical-Data-on-Novel-Off-the-Shelf-Natural-Killer-Cell-Therapy-ACE1702-for-HER2-Expressing-Solid-Tumors-Using-Antibody-Cell-Conjugation-Technology-in-the-Jo.html
https://www.globenewswire.com/news-release/2021/05/19/2232444/0/en/Acepodia-Presents-Data-on-its-Allogeneic-Natural-Killer-Like-Gamma-Delta-T-Cell-Therapy-ACE1831-in-Development-for-Hematological-Cancers.html
Market Place
Share 
